Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 12 selected

Guidance programme

Showing 76 to 100 of 1247

TitleReference numberPublishedLast updated
Dapagliflozin for treating chronic kidney diseaseTA1075
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)TA1078
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesTA1073
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Spesolimab for treating generalised pustular psoriasis flaresTA1070
Caesarean birthNG192
Efgartigimod for treating antibody-positive generalised myasthenia gravisTA1069
Linzagolix for treating symptoms of endometriosisTA1067
Headaches in over 12s: diagnosis and managementCG150
Somapacitan for treating growth hormone deficiency in people 3 to 17 yearsTA1066
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)TA1068
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA1065
Abortion careNG140
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA1064
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatmentTA1063
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitorTA1062
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTA1059
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Falls: assessment and prevention in older people and in people 50 and over at higher riskNG249
Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and overHST33
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1055

Results per page

  1. 10
  2. 25
  3. 50
  4. All